This section has information on Considerations for Antiretroviral Use in Patients with Coinfections. Please click on the below links or follow the table of contents to access the information you are looking for. TB/HIV HBV/HIV HCV/HIV
AU Comment: Australian epidemiology Approximately 5% of Australia’s 26,500 people living with HIV also have chronic hepatitis B. GESA Australian consensus recommendations also suggests HDV testing in the context of HIV/HBV coinfection.Reference: Hepatitis B Consensus Statement Working Group. Australian consensus recommendations for the management of hepatitis B infection. Melbourne: Gastroenterological Society of Australia, 2022. Panel’s …
AU Comment: Hepatitis C Treatment in the Australian Context The PBS lists the following all-oral pan genotypic regimens for the treatment of chronic hepatitis C infection in Australia, regardless of liver disease stage or ongoing drug and alcohol use. Treatment naïve: Sofosbuvir + Velpatasvir OR Glecaprevir + Pibrentasvir Treatment experienced: sofosbuvir+velpatasvir+ voxilaprevir (Vosevi) Regimens should …
AU Comment: Timing of ART commencement in OIs Data on when to commence ART in HIV patients with an opportunistic infection (OI) are mostly derived from studies undertaken in resource-limited countries where medical care and patient follow-up may be different to Australia. In general, ART should be commenced within 2 weeks of commencing treatment for …
This section has information on Special Patient Populations. Please click on the below links or follow the table of contents to access the information you are looking for. Women with HIV Substance Use Disorders and HIV HIV-2 Infection Early (Acute and Recent) HIV Infection Transgender People with HIV HIV and the Older Person Adolescents and …
AU Comment: Diagnosis of early HIV infection in Australia When acute HIV-1 infection is suspected, and an anti-HIV antibody and/or antibody/antigen combo test is negative or the western blot is indeterminate, other suitable test options include a nucleic acid test for HIV. However, proviral DNA tests are not widely available in Australia and HIV viral …
AU Comment: Adolescents and young adults with HIV in Australia In 2021, 4/745 (0.5%) of all new HIV notifications in Australia were among individuals aged 19 years or younger, with the majority (3/4) of these notifications among those aged 15-19 years. Reference: King J, McManus H, Kwon A, Gray A, McGregor S. HIV, viral hepatitis …
AU Comment: HIV-2 Infection in Australia HIV-2 is uncommon in Australia. Diagnosis of HIV-2 in Australia can be difficult because of the cross-reaction of serological tests with HIV-1 proteins. St Vincent’s Hospital, Sydney, and the Victorian Infectious Diseases Reference Laboratory (VIDRL) offers an HIV-2 western blot confirming HIV-2 infection by reactivity to specific HIV-2 glycoproteins. …
AU Comment: Australian Cardiovascular risk calculator An HIV-specific cardiovascular risk calculator has been developed based on data from the D:A:D study (including the use of specific antiretroviral agents), but has not been validated in other populations. The Australian Absolute Cardiovascular Disease Risk Calculator is recommended for use to estimate an individual’s five-year risk of cardiovascular …
Key Considerations and Recommendations Substance use disorders (SUDs) are prevalent among people with HIV and contribute to poor health outcomes; therefore, screening for SUDs should be a routine part of clinical care (AII). The most commonly used substances among people with HIV include the following (listed in alphabetical order): alcohol, benzodiazepines, cannabinoids, club drugs, opioids, …